- About Overview
- Diversity, Equity, and Inclusion
- Honors and Awards
- Facts and Figures
- Support the School
- Contact Us
- Dean’s Office
- Dean’s Office Overview
- Education Unit
- Office of Faculty Academic Affairs
- Office of Administration
- Org Chart
- Patient Care
Asthma drug response in racially diverse children
The first pharmacogenetic whole genome sequencing study of albuterol response
By Katherine Krebs / Wed Mar 7, 2018
Sam S. Oh
“Whole genome sequencing of pharmacogenetic drug response in racially diverse children with asthma” has been published by the American Journal of Respiratory and Critical Care Medicine (ARJCCM). “This is a huge win for the NHLBI’s TOPMed program, UCSF, and our lab,” said senior author Esteban G. Burchard, MD, MPH.
Trans-Omics for Precision Medicine (TOPMed) is a program of the National Heart, Lung, and Blood Institute (NHLBI) that advances precision medicine, an emerging approach to disease prevention and treatment that considers the unique genes and environment of each patient.
“We published the first pharmacogenetic whole genome sequencing study of albuterol response. We demonstrated that there are common and rare genetic variants that drive bronchodilator drug response to albuterol among three racial groups of minority children with asthma. African Americans and Puerto Ricans have the highest asthma prevalence, morbidity, and mortality but lowest drug response to asthma therapies,” he said.
“Genetic research in diverse populations is very important; the new PCSK inhibitors for cholesterol were identified in African Americans and completely missed in populations of European-origin,” added Burchard.
UCSF collaborators include: Angel C.Y. Mak, MPhil, PhD; Marquitta J. White, MS, PhD; Walter L. Eckalbar, PhD; Zachary A. Szpiech, PhD; Sam S. Oh, PhD, MPH; Donglei Hu, PhD; Pagé Goddard; Scott Huntsman, MS; Dara G. Torgerson, PhD; Celeste Eng, BS; Sandra Salazar; Kevin L. Keys, PhD; Jennifer Liberto, MS; Thomas J. Nuckton, MD; Thomas A. Nguyen; Pui-Yan Kwok, MD, PhD; Nadav Ahituv, PhD; Elad Ziv, MD; Noah Zaitlen, PhD; Ryan Hernandez, PhD.
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.